Stock data
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN) reported net income of -US$117.30M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-10-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$123.17M | -US$117.30M | — |
| 2024 | — | — | -US$62.30M | -US$55.14M | — |
| 2023 | — | — | -US$26.06M | -US$99.92M | — |
| 2022 | — | — | -US$19.43M | -US$24.46M | — |
Quarterly results
Data as of 2026-07-31
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-07-31 | — | -US$32.50M | — |
| 2026-04-30 | — | -US$30.23M | — |
| 2026-01-31 | — | -US$29.75M | — |
| 2025-10-31 | — | -US$37.88M | — |
| 2025-07-31 | — | -US$28.99M | — |
| 2025-04-30 | — | -US$25.82M | — |
| 2025-01-31 | — | -US$24.62M | — |
| 2024-10-31 | — | -US$15.30M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.